{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T19:17:47Z","timestamp":1769282267332,"version":"3.49.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CO912\/2-1, IM97\/7-2"],"award-info":[{"award-number":["CO912\/2-1, IM97\/7-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["03Z22JN12, 01EO1502"],"award-info":[{"award-number":["03Z22JN12, 01EO1502"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hemolytic-uremic syndrome (HUS) can occur as a systemic complication of infections with Shiga toxin (Stx)-producing <jats:italic>Escherichia coli<\/jats:italic> and is characterized by microangiopathic hemolytic anemia and acute kidney injury. Hitherto, therapy has been limited to organ-supportive strategies. Erythropoietin (EPO) stimulates erythropoiesis and is approved for the treatment of certain forms of anemia, but not for HUS-associated hemolytic anemia. EPO and its non-hematopoietic analog pyroglutamate helix B surface peptide (pHBSP) have been shown to mediate tissue protection <jats:italic>via<\/jats:italic> an innate repair receptor (IRR) that is pharmacologically distinct from the erythropoiesis-mediating receptor (EPO-R). Here, we investigated the changes in endogenous EPO levels in patients with HUS and in piglets and mice subjected to preclinical HUS models. We found that endogenous EPO was elevated in plasma of humans, piglets, and mice with HUS, regardless of species and degree of anemia, suggesting that EPO signaling plays a role in HUS pathology. Therefore, we aimed to examine the therapeutic potential of EPO and pHBSP in mice with Stx-induced HUS. Administration of EPO or pHBSP improved 7-day survival and attenuated renal oxidative stress but did not significantly reduce renal dysfunction and injury in the employed model. pHBSP, but not EPO, attenuated renal nitrosative stress and reduced tubular dedifferentiation. In conclusion, targeting the EPO-R\/IRR axis reduced mortality and renal oxidative stress in murine HUS without occurrence of thromboembolic complications or other adverse side effects. We therefore suggest that repurposing EPO for the treatment of patients with hemolytic anemia in HUS should be systematically investigated in future clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1010882","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T05:24:17Z","timestamp":1663910657000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting the innate repair receptor axis via erythropoietin or pyroglutamate helix B surface peptide attenuates hemolytic-uremic syndrome in mice"],"prefix":"10.3389","volume":"13","author":[{"given":"Sophie","family":"Dennhardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiebke","family":"Pirschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianka","family":"Wissuwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Imhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan T.","family":"Kielstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Hennig-Pauka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Amann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Gunzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina M.","family":"Coldewey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/toxins12020067","article-title":"Shiga toxin-associated hemolytic uremic syndrome: A narrative review","volume":"12","author":"Joseph","year":"2020","journal-title":"Toxins (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-012-2383-6","article-title":"Long-term outcomes of shiga toxin hemolytic uremic syndrome","volume":"28","author":"Spinale","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq511","article-title":"Oxidative stress status during the acute phase of haemolytic uraemic syndrome","volume":"26","author":"Ferraris","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"203512","DOI":"10.1155\/2014\/203512","article-title":"L-arginine\/NO pathway is altered in children with haemolytic-uraemic syndrome (HUS)","volume":"2014","author":"Kanzelmeyer","year":"2014","journal-title":"Oxid Med Cell Longev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12124","article-title":"The oxidative stress induced in vivo by shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome","volume":"173","author":"Gomez","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2014.1.444","article-title":"Thrombotic microangiopathy and indications for therapeutic plasma exchange","volume":"2014","author":"Adamski","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B7","volume-title":"Infektionsepidemiologisches jahrbuch meldepflichtiger krankheiten f\u00fcr 2020","year":"2020"},{"key":"B8","unstructured":"Bolet\u00edn integrado de vigilancia N560 SE30 20212021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13099-017-0179-8","article-title":"Comparison of clinical and immunological findings in gnotobiotic piglets infected with escherichia coli O104:H4 outbreak strain and EHEC O157:H7","volume":"9","author":"W\u00f6chtl","year":"2017","journal-title":"Gut Pathog"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01459","article-title":"Modeling hemolytic-uremic syndrome: In-depth characterization of distinct murine models reflecting different features of human disease","volume":"9","author":"Dennhardt","year":"2018","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.12.024","article-title":"Divergent roles of haptoglobin and hemopexin deficiency for disease progression of shiga-toxin-induced hemolytic-uremic syndrome in mice","volume":"101","author":"Pirschel","year":"2022","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000001558","article-title":"Involvement of NF-kappaB1 and the non-canonical NF-kappaB signaling pathway in the pathogenesis of acute kidney injury in shiga-toxin-2-induced hemolytic-uremic syndrome in mice","volume":"56","author":"Sobbe","year":"2021","journal-title":"Shock"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006050419","article-title":"A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease","volume":"17","author":"Keepers","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00592-08","article-title":"Mouse model of hemolytic-uremic syndrome caused by endotoxin-free shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody","volume":"76","author":"Sauter","year":"2008","journal-title":"Infect Immun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805594105","article-title":"Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin","volume":"105","author":"Brines","year":"2008","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406491101","article-title":"Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor","volume":"101","author":"Brines","year":"2004","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s13054-014-0526-9","article-title":"Erythropoietin and organ protection: lessons from negative clinical trials","volume":"18","author":"Pearl","year":"2014","journal-title":"Crit Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071533","article-title":"Efficacy and safety of epoetin alfa in critically ill patients","volume":"357","author":"Corwin","year":"2007","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.564872","article-title":"Recombinant human erythropoietin in the treatment of acute ischemic stroke","volume":"40","author":"Ehrenreich","year":"2009","journal-title":"Stroke"},{"key":"B20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2015.02.005","article-title":"Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin","volume":"151","author":"Collino","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.22092\/ari.2021.355849.1728","article-title":"Assessment of the nephroprotective properties of the erythropoietin mimetic peptide and infliximab in kidney ischemia-reperfusion injury in rats","volume":"76","author":"Netrebenko","year":"2021","journal-title":"Arch Razi Inst"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2012.00093","article-title":"Delayed administration of pyroglutamate helix b surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury","volume":"18","author":"Patel","year":"2012","journal-title":"Mol Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2014.00215","article-title":"ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes","volume":"20","author":"Brines","year":"2015","journal-title":"Mol Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2013.00122","article-title":"ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density","volume":"19","author":"Dahan","year":"2013","journal-title":"Mol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.118","article-title":"Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the beta-common receptor","volume":"84","author":"Coldewey","year":"2013","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.011908","article-title":"Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the beta-common receptor","volume":"6","author":"Khan","year":"2013","journal-title":"Dis Model Mech"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.22.2827","article-title":"Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial","volume":"288","author":"Corwin","year":"2002","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-2710.2004.00552.x","article-title":"Use of exogenous erythropoietin in critically ill patients","volume":"29","author":"MacLaren","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-471441","article-title":"Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: A longitudinal study","volume":"122","author":"Pasricha","year":"2013","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/aas.13664","article-title":"Association between transfusion of blood products and acute kidney injury following cardiac surgery","volume":"64","author":"Rasmussen","year":"2020","journal-title":"Acta Anaesthesiol Scand"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb05020.x","article-title":"Serum erythropoietin and serum transferrin receptor levels in aplastic anaemia","volume":"88","author":"Schrezenmeier","year":"1994","journal-title":"Br J Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s004670050443","article-title":"Low levels of serum erythropoietin in children with endemic hemolytic uremic syndrome","volume":"12","author":"Exeni","year":"1998","journal-title":"Pediatr Nephrol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.8.1987.1987","article-title":"Effect of inflammatory cytokines on hypoxia-induced erythropoietin production","volume":"79","author":"Faquin","year":"1992","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105093241907","article-title":"Erythropoietin","volume":"324","author":"Erslev","year":"1991","journal-title":"N Engl J Med"},{"key":"B35","unstructured":"Supportive therapie bei onkologischen PatientInnen - langversion 1.02016"},{"key":"B36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.35","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","year":"2012","journal-title":"Kidney Inter Supplement"},{"key":"B37","unstructured":"H\u00e4molytisch-ur\u00e4misches syndrom im kindesalter2022"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05474-9","article-title":"Erythropoietin in children with hemolytic uremic syndrome: A pilot randomized controlled trial","volume":"37","author":"Balestracci","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2911-7","article-title":"Early erythropoietin in post-diarrheal hemolytic uremic syndrome: A case-control study","volume":"30","author":"Balestracci","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-008-1087-4","article-title":"Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome: a randomized prospective pilot trial","volume":"24","author":"Pape","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2016.59.2.100","article-title":"Recombinant human erythropoietin therapy for a jehovah\u2019s witness child with severe anemia due to hemolytic-uremic syndrome","volume":"59","author":"Woo da","year":"2016","journal-title":"Korean J Pediatr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in shiga-toxin-producing e. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e036527","DOI":"10.1136\/bmjopen-2019-036527","article-title":"Identification of cardiovascular and molecular prognostic factors for the medium-term and long-term outcomes of sepsis (ICROS): protocol for a prospective monocentric cohort study","volume":"10","author":"Coldewey","year":"2020","journal-title":"BMJ Open"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780090710","article-title":"More powerful procedures for multiple significance testing","volume":"9","author":"Hochberg","year":"1990","journal-title":"Stat Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00357-014-9161-z","article-title":"Ward\u2019s hierarchical agglomerative clustering method: Which algorithms implement ward\u2019s criterion","volume":"31","author":"Murtagh","year":"2014","journal-title":"J Classif"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-0227-y","article-title":"Cellular adaptation to hypoxia through hypoxia inducible factors and beyond","volume":"21","author":"Lee","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1159\/000496618","article-title":"Endogenous erythropoietin and hepatic dysfunction in acute kidney injury requiring renal replacement therapy","volume":"142","author":"Matsuura","year":"2019","journal-title":"Nephron"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/BF02551350","article-title":"Erythropoietin in patients with acute renal failure and continuous veno-venous haemofiltration","volume":"29","author":"Morgera","year":"1997","journal-title":"Int Urol Nephrol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/cc2902","article-title":"Erythropoietin and renin as biological markers in critically ill patients","volume":"8","author":"Tamion","year":"2004","journal-title":"Crit Care"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12656","article-title":"Erythropoietin concentration in acute kidney injury is associated with insulin-like growth factor-binding protein-1","volume":"21","author":"Yamashita","year":"2016","journal-title":"Nephrol (Carlton)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106483","article-title":"Epidemic profile of shiga-toxin-producing escherichia coli O104:H4 outbreak in Germany","volume":"365","author":"Frank","year":"2011","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.362","article-title":"Identification of the renal erythropoietin-producing cells using transgenic mice","volume":"44","author":"Maxwell","year":"1993","journal-title":"Kidney Int"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1309\/UMW9-D06Q-M94Q-JGH2","article-title":"Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic escherichia coli","volume":"118","author":"Gunzer","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2016-311377","article-title":"Treatment and management of children with haemolytic uraemic syndrome","volume":"103","author":"Walsh","year":"2018","journal-title":"Arch Dis Child"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.19.8725","article-title":"Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice","volume":"88","author":"Semenza","year":"1991","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.13.5680","article-title":"Hypoxia-inducible nuclear factors bind to an enhancer element located 3\u2019 to the human erythropoietin gene","volume":"88","author":"Semenza","year":"1991","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.3390\/ijms21165611","article-title":"Hypoxia and HIF signaling: One axis with divergent effects","volume":"21","author":"Corrado","year":"2020","journal-title":"Int J Mol Sci 21"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004330","article-title":"How I treat renal anemia","volume":"136","author":"Fishbane","year":"2020","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","article-title":"Renal association clinical practice guideline on anaemia of chronic kidney disease","volume":"18","author":"Mikhail","year":"2017","journal-title":"BMC Nephrol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2016.05.045","article-title":"Erythropoietin attenuates renal and pulmonary injury in polymicrobial induced-sepsis through EPO-r, VEGF and VEGF-R2 modulation","volume":"82","author":"Heitrich","year":"2016","journal-title":"BioMed Pharmacother"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.3390\/ijms21103453","article-title":"Erythropoietin ameliorates Ischemia\/Reperfusion-induced acute kidney injury via inflammasome suppression in mice","volume":"21","author":"Kwak","year":"2020","journal-title":"Int J Mol Sci 21"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2017.01.010","article-title":"Erythropoietin attenuates experimental haemorrhagic shock-induced renal damage through an iNOS- dependent mechanism in male wistar rats","volume":"48","author":"Ranjbaran","year":"2017","journal-title":"Injury"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.08.087","article-title":"Erythropoietin attenuates LPS-induced microvascular damage in a murine model of septic acute kidney injury","volume":"107","author":"Stoyanoff","year":"2018","journal-title":"BioMed Pharmacother"},{"key":"B64","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1471-2369-13-132","article-title":"Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study","volume":"13","author":"de Seigneux","year":"2012","journal-title":"BMC Nephrol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"R254","DOI":"10.1186\/cc13081","article-title":"Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety","volume":"17","author":"Kim","year":"2013","journal-title":"Crit Care"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz068","article-title":"Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory post hoc analyses from an open-label randomized trial","volume":"13","author":"Guillemet","year":"2020","journal-title":"Clin Kidney J"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01360212","article-title":"Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial","volume":"7","author":"Sureshkumar","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.25","article-title":"Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial)","volume":"77","author":"Endre","year":"2010","journal-title":"Kidney Int"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2012.27.5.506","article-title":"Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting","volume":"27","author":"Oh","year":"2012","journal-title":"J Korean Med Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.080983","article-title":"Disruption of e-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells","volume":"175","author":"Zheng","year":"2009","journal-title":"Am J Pathol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-018-0052-5","article-title":"Restoration of e-cadherin by PPBICA protects against cisplatin-induced acute kidney injury by attenuating inflammation and programmed cell death","volume":"98","author":"Gao","year":"2018","journal-title":"Lab Invest"},{"key":"B72","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41419-019-1589-y","article-title":"3-deazaneplanocin a protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of e-cadherin expression","volume":"10","author":"Ni","year":"2019","journal-title":"Cell Death Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.742483","article-title":"Fundamental mechanisms of the cell death caused by nitrosative stress","volume":"9","author":"Wang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2004.04.003","article-title":"NO bioavailability, endothelial dysfunction, and acute renal failure: new insights into pathophysiology","volume":"24","author":"Goligorsky","year":"2004","journal-title":"Semin Nephrol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1503\/cjs.004811","article-title":"Inhibiting inducible nitric oxide synthase with rutin reduces renal ischemia\/reperfusion injury","volume":"56","author":"Korkmaz","year":"2013","journal-title":"Can J Surg"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118681","article-title":"In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia","volume":"97","author":"Noiri","year":"1996","journal-title":"J Clin Invest"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.1156","article-title":"Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation via protein kinase c","volume":"207","author":"Sharma","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2011.11.013","article-title":"Recombinant human erythropoietin reduces rhabdomyolysis-induced acute renal failure in rats","volume":"43","author":"Yang","year":"2012","journal-title":"Injury"},{"key":"B79","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jneuroim.2014.01.006","article-title":"Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat","volume":"268","author":"Chen","year":"2014","journal-title":"J Neuroimmunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1159\/000475434","article-title":"Erythropoietin-derived peptide protects against acute lung injury after rat traumatic brain injury","volume":"41","author":"Liu","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.107","article-title":"Mitochondrial energetics in the kidney","volume":"13","author":"Bhargava","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1542\/peds.47.4.776","article-title":"Hyperlipidemia in the hemolytic-uremic syndrome","volume":"47","author":"Kaplan","year":"1971","journal-title":"Pediatrics"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.09.108","article-title":"Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity","volume":"493","author":"Sun","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.305360","article-title":"Gut microbiota-dependent trimethylamine n-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease","volume":"116","author":"Tang","year":"2015","journal-title":"Circ Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00363.2017","article-title":"NMR spectroscopy and electron microscopy identification of metabolic and ultrastructural changes to the kidney following ischemia-reperfusion injury","volume":"314","author":"Chihanga","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1039\/C5MB00492F","article-title":"Discovery of urinary metabolomic biomarkers for early detection of acute kidney injury","volume":"12","author":"Won","year":"2016","journal-title":"Mol Biosyst"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.11.007","article-title":"Kidney-secreted erythropoietin lowers lipidemia via activating JAK2-STAT5 signaling in adipose tissue","volume":"50","author":"Li","year":"2019","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1010882\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T05:24:26Z","timestamp":1663910666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1010882\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2022.1010882"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1010882","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"article-number":"1010882"}}